A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis
Latest Information Update: 20 Jun 2023
At a glance
- Drugs Latozinemab (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Alector
- 14 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2021 New trial record